Arbutus Biopharma (NASDAQ: ABUS) is one of the many biotech companies focused on the research and development of Hepatitis B therapeutics. What helps make the company stand out from the crowd is ...

What happened Shares of Arbutus Biopharma (ABUS -1.73%) were trading down by 12.6% as of 11:04 a.m. ET Tuesday. The decline came after the company announced that the Food and Drug Administration ...

Quiver AI Summary Arbutus Biopharma Corporation announced plans to initiate a Phase 2b clinical trial in the first half of 2025 after reporting promising results from its Phase 2a trial, where a ...

Financials According to the 10-Q SEC Filing, Arbutus Biopharma announced that it had $151.9 million in cash, cash equivalents and investments as of September 30, 2021.

(ABUS) on Wednesday reported second-quarter net income of $2.5 million, after reporting a loss in the same period a ...

WARMINSTER, Pa. and OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive ...

About Arbutus Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic ...

Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic ...

What happened Shares of Arbutus Biopharma (ABUS 2.10%) rocketed higher on Wednesday morning in response to a court ruling in its favor. The stock was up 70.2% at 11:41 a.m. on Wednesday. So what ...